Objective: Parkinson disease (PD), a devastating neurodegenerative disorder, affects motor abilities and cognition as well. It is not clear whether the proapoptotic protein, Bid, is involved in tumor necrosis factor death receptor I (TNFRI)-mediated destructive signal transduction pathways such as cell dysfunction or neurodegeneration in the temporal cortex of patients with PD.
Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Apoptosis may be involved in dopaminergic cell death in sporadic and familial PD. [1] [2] [3] [4] [5] [6] [7] However, whether other brain regions undergo the destructive signal pathways is still unknown. Cell apoptosis is regulated by a wide number of factors, such as tumor necrosis factor (TNF) and Fas ligand. Evidence implicates neuroinflammation from TNF as the fundamental piece in the pathogenesis of PD. 8 -12 Elevated levels of TNF in the CSF and postmortem brains of patients with PD suggest that this proinflammatory cytokine plays an important role in the pathophysiology of the disease. Elucidation of the mechanisms underlying neuroinflammation in PD may contribute to new and effective therapies, especially for cognitive decline of patients with PD. TNF receptor subtype I (TNFRI) contains a "death domain" (DD) that is associated with DD-containing adaptor proteins, including TNFRI-associated DD protein (TRADD), Fas-associated DD (FADD), or receptorinteracting protein. The detailed apoptotic pathway that may be mediated by TNFRI is still unknown in PD, although studies have shown elevated TNFRI levels in the substantia nigra of patients with PD. 13 Bid is a proapoptotic protein of the Bcl-2 family that is crucial for death receptormediated apoptosis and is activated posttranslationally via caspase-8-mediated cleavage into a truncated form, tBid. 14 -16 In the present study, we have identified an activated Bid-mediated destructive pathway in the temporal cortex of patients with PD, suggesting that they might contribute to cognitive decline manifestation.
METHODS Standard protocol approvals, registrations, and patient consents. All subjects or their legally authorized representatives sign an informed consent to research and autopsy; the research has been approved by the institutional review board. Brain tissue was obtained from the Banner Sun Health Research Institute brain and body donation program (BBDP), Sun City, AZ. 17
Acquisition of samples. The research subjects were recruited primarily from the Sun City retirement communities located in the northwest metropolitan region of Phoenix, AZ. These communities have a population of approximately 900,000, an average age of 72 years, and a minimum age of 55 years. The BBDP is unique for its rapid autopsy program (median postmortem interval is 2.8 hours), allowing the provision of unusually highquality brain tissue. The study subjects consisted of 15 nonpathologic control (NPC) subjects (at age of 78 to 90 years) and 15 patients with PD (at age of 72 to 90 years, disease duration of 14.4 Ϯ 8.4 years). The subject profiles are presented in table 1.
Clinical diagnosis and pathologic confirmation.
Human subjects were specifically chosen with no dementia and PD in the temporal cortex who might be showing early changes but not be end-stage as might be seen in individuals with dementia. The criteria for Alzheimer disease (AD) are defined by NIA-Reagan "intermediate or high" 18 and pathologic Consortium to Establish a Registry for Alzheimer's Disease neuritic plaque density 19 as well as Braak staging. 20 The detail information is shown in table e-1 on the Neurology ® Web site at www.neurology.org. PD diagnosis was determined when there were at least 2 of the cardinal clinical signs of PD as well as pathologic evidence of Lewy bodies and pigmented neuron loss in the substantia nigra (SN). Scores for brain regions are based on Dementia with Lewy Body Consortium density estimates 21 and Unified Staging System for Lewy body disorders. 22 The detail information is shown in table e-2. Patients who met pathologic criteria for PD are levodopa responsive. NPCs were selected based on the absence of a clinical history of parkinsonism or dementia and the absence of Lewy bodies on neuropathologic examination.
Brain tissue preparation. Protein was extracted from homogenates of frozen tissue from the gray matter of the temporal cortex in 15 PD cases and 15 controls. Approximately 500 mg of tissue was homogenized in phosphate-buffered saline containing 1% Triton X-100 and 0.1% sodium dodecyl sulfate (SDS) (pH 7.0) plus proteinase inhibitors, and it was centrifuged at 14,000 rpm for 30 minutes. The protein concentration in the supernatant was measured with a Bio-Rad protein assay kit. A total of 50 g of protein was mixed with 1:1 of sample buffer (25 mM Tris, 250 mM Glycine, pH 7.0) and loaded on a 12% SDS polyacrylamide gel electrophoresis (SDS-PAGE) gel. The protein was then transferred to a PDVF membrane.
ELISA. The content of TNFRI in the lysed extracts was determined using a commercially available ELISA kit for human TNFRI (R&D System). Dilution curve homogenate samples of the brain were parallel to the standard dilution curve. The assay followed the manufacturer's recommended procedures. The absorbance was measured at 450 nm with an automatic wavelength correction of 540 nm. The experiments were repeated 3 times.
Immunoprecipitation. For the immunoprecipitation of TRADD, 500 g of brain extracts in a 300 L volume containing 20 g anti-TRADD polyclonal antibody (catalog: ab18914, Abcam) was incubated at 4°C overnight. A total of 20 L of Protein-G agarose (Pierce) was then mixed with the samples and incubated with orbitary rotation at 4°C for 4 hours. The beads were collected and resuspended in 50 L of SDS-PAGE loading dye and heated at 95°C for 5 minutes. A total of 10 L of each sample was separated by 12% SDS-PAGE gel and transferred to PDVF membranes.
Immunoblotting. Western blots were probed with the following antibodies: anti-TRADD monoclonal antibody (1:500, catalog: sc-46653, Santa Cruz); anti-Bid polyclonal antibody (1: 5,000, catalog: AF846, R&D Systems); anti-cytochrome c monoclonal antibody (1:5,000, clone: 7H8.2C12, catalog: ab13575, Abcam); and anti-caspase-3 polyclonal antibody (1: 5,000, catalog: sc-7148, Santa Cruz). Blots were also probed with anti-␤-actin monoclonal antibody (1:5,000, catalog: #1978, Sigma) as a loading control. For mitochondria samples, the blots were performed with anti-Cox IV monoclonal antibody (1:5,000, clone: 20E8C12, catalog: ab14744, Abcam) as a mitochondrial loading control. The protein levels were normalized to ␤-actin or Cox IV (for mitochondria samples) and indicated in arbitrary units.
Immunohistochemistry.
The immunohistostaining was performed as described previously. 23, 24 Fresh tissues of the temporal cortex were postfixed with 4% paraformaldehyde and sectioned to 30 m. Pretreatment of sections was performed with 0.3% triton X-100 and blocked with 10% goat serum for 30 minutes. Primary antibodies were incubated with polyclonal rabbit anti-Bid (1:400, clone: Y8, catalog: ab32060, Abcam), mouse anti-NeuN (MAB377, Millipore, Billerica, MA), monoclonal mouse anti-glial fibrillary acid protein (GFAP, 1:5,000, clone: SMI22, catalog: SMI-22R, Covance), mouse anti-human CD45 (1:400, clone: F10-89-4, catalog: MCA87, Serotec) overnight at 4°C. Secondary antibodies of goat against mouse or rabbit immunoglobulin G with fluorescence 488 or 568 (1:1,000; Invitrogen, Carlsbad, CA) were incubated for 30 minutes. The images were taken with BX63 microscope (Olympus, Tokyo, Japan).
Mitochondria isolation. Mitochondria were isolated from approximately 100 mg of gray matter tissue from the temporal cortex using a mitochondria isolation kit (BioChain Institute Inc, Hayward, CA). The isolation procedure followed the manufacturer's recommended procedures. Protein concentration was measured with Bio-Rad protein assay kit. Samples for separation on a 12% SDS-PAGE gel were prepared as described in the immunoprecipitation section.
Caspase-3 activity assay. Caspase-3 activity was determined using a caspase-3 activity kit according to the manufacturer's protocol (Calbiochem). Briefly, the colorimetric assay was conducted with an equal amount of brain lysate combined with the fluorescent labeled DEVD substrate in a 96-well plate. The plate was incubated at 37°C for 2 hours and the fluorescence was measured at 400 nm and 505 nm. The amount of luminescence expressed as relative light units reflects caspase activity. These assays were performed in triplicate.
Statistical analysis. Data were presented as mean Ϯ SEM.
Differences in means were determined by an unpaired t test. A probability value of p Ͻ 0.05 was considered statistically significant.
RESULTS TNFRI signaling is elevated in PD brains.
Quantification of TNFRI protein levels in the temporal cortex of PD and age-matched NPC brains were determined by ELISA. As shown in figure 1A , the levels of TNFRI in PD brains (2.22 Ϯ 0.24 ng/ mg) was higher ( p Ͻ 0.05) than that in NPC brains (1.56 Ϯ 0.12 ng/mg). The activation of TNFRI recruited several adaptor proteins containing DDs. We examined the expression of TRADD, a molecule involved in a TNFRI-mediated destructive signal transduction pathway, in the temporal cortex using immunoprecipitation. We observed a band of TRADD around 34 kD ( figure 1B ). Density assay showed increased TRADD levels in PD brains (figure 1C, p Ͻ 0.01).
Bid expression in neurons and activated astrocytes as well as cleaved Bid translocation to the mitochondria
in PD brains. To verify whether Bid expression is activated and in which cell type in brains, immunostaining was performed with the brain sections from the temporal cortex. We found Bid expression in most of the neurons (NeuN, a neuron marker, figure  2A ) and some activated astrocytes (GFAP, an astrocyte marker, figure 2B ) but not in activated microglia (CD45, an activated microglial marker, figure 2C ). Both forms of Bid, full length Bid (ϳ22 kD) and tBid (ϳ14 kD), were detected in temporal cortex brain lysate and mitochondria extractions. The levels of full-length Bid in the cytosol were increased in PD brains compared to NPC brains. A dramatically increased level of tBid was detected in all PD brains, but only existed in a few NPC brains (figure 2, D and E). In the mitochondria, there was an increase in full-length Bid expression exclusively in PD group compared to NPC brains. Similar results were observed in tBid levels (figure 2, F and G); tBid was not found in mitochondria extractions from NPC brain samples.
Cytochrome c is released from the mitochondria in PD brains. The mitochondria from the temporal cortex were isolated. Western blot was performed and results showed that levels of cytoplasmic cytochrome c were increased in PD brain samples after normalization to ␤-actin level ( figure 3, A and B , p Ͻ 0.01). However, the levels of cytochrome c in mitochondria were decreased after normalization to Cox IV level (figure 3, C and D, p Ͻ 0.01), suggesting that the translocation of tBid to mitochondria causes a significant cytochrome c release from the mitochondria. 
Activity of caspase-3 is increased in PD brains.
To address the particular role of caspases in TNFRImediated destructive signal transduction pathway, we used both Western blot and procaspase-3 activity assay. Three bands were detected using Western blot, 1 fragment of procaspase-3 (32 kD), and 2 cleaved forms of proteins (21 kD and 12 kD). There was an increase of procaspase-3 and its cleaved fragments in the temporal cortex of PD brains compared to NPC brains ( figure 4A ). Procaspase-3 activity was detected and we found an increased caspase activity in PD brains compared to NPC brains, which is in agreement with the Western blot results ( figure 4B ).
No changes are found in Bid signal components between controls without dementia and preclinical AD among the patients with PD. According to the current criteria for a pathologic diagnosis of preclinical AD, in the 15 cases of patients with PD listed in table e-1, 6 cases of patients with PD accompany the cortical changes of preclinical AD (moderate/frequent neuritic plaques and Braak III/IV of neurofibrillary tangles). To clarify the possible influences of preclinical AD-like changes in patients with PD, the values of each protein band density of Western blotting were measured. Results showed no significant differences in the expression levels of TNFRI, TRADD, Bid, tBid, cytochrome c, and procaspase 3 and cleaved caspase 3 between no dementia and brain preclinical AD changes among all patients with PD.
DISCUSSION Available evidence suggests that patients with PD exhibit neurodegeneration not only in the dopaminergic neurons in SN, but also other brain regions including the cortex. The mechanisms underlying the neurodegenerative process remain elusive. In the present study, we found that the cleavage of Bid and its truncated tBid translocation to the mitochondria are implicated in the TNFRImediated signaling pathway in the temporal cortex of PD brains. These findings might provide a mechanistic link to how the death receptor leads to the activation of Bid, the dysfunction of mitochondria, and the consequent activation of caspases in the cortex regions of PD brains (figure e-1). We previously reported that TNFRI levels are elevated in the cortex from AD brains. 25 Here, we found an elevated expression of TNFRI and its adaptor protein, TRADD, in the temporal cortex of parkinsonian brains. All of these suggest a possible association of death receptors with cell death in neurodegenerative disorders. A likely interaction partner for TRADD may be FADD, which can then interact with procaspase-8. Activation of procaspase-8 through self-cleavage leads to a series of downstream events, including activation of procaspase-3 and induction of mitochondrial damage. 26, 27 Bid is a unique BH3-only molecule of Bcl-2 family, 15 which is largely present in cytosol and is involved in the cellular destructive process mediated by TNFRI death receptor. A truncated fragment tBid is generated from a proteolytic digestion at Asp-59, a site with a conserved caspase-8-cleavage sequence. 28 Upon the stimulation of a particular death signal, tBid translocates to the mitochondria and induces cytochrome c release. 14,29 -31 This is similar to a previ- ous report showing that cells depleted of Bid by immunoprecipitation are no longer able to induce cytochrome c release. 32 Bid-induced cytochrome c release is mediated by 2 different mechanisms. One is responsible for the initial release of free cytochrome c in the intermembrane space through a Bakdependent mechanism. The other causes a dramatic remodeling of mitochondrial cristae, which mobilize cytochrome c storage. Effects of tBid on the mitochondria may not be limited to the induction of cytochrome c release, but may include other changes in mitochondrial physiology such as mitochondrial redistribution and loss of mitochondrial ⌬m in the cells. 33 This portion of cytochrome c constitutes the majority (85%) of total release. 34 The released cytochrome c then binds with Apaf-1 to form the apoptosome, a multimeric Apaf-1 and cytochrome c complex. Only the caspase-9 binding to the apopto-some is able to efficiently cleave and activate downstream executioner caspases such as caspase-3. 16, 35 These executioner caspases will then cleave intracellular substrates, leading to chromatin condensation and DNA fragmentation. As shown in figure e-1, TNFRI can directly activate caspase-3 through caspase-8. This might be due to the amplification of caspase activation and the involvement of additional mitochondrial dysfunction.
Our finding demonstrated that Bid is largely activated in the neurons of the temporal cortex from patients with PD as well as the activation of the entire TNFRI-Bid death signaling pathway in the cortex relevant to nonmotor PD. The results are similar to the observation of TNFRI-engaged hepatocyte apoptosis in which Bid is required for TNF␣-and Fasinduced apoptosis through a mitochondrial pathway. 34 Our data might in part explain the possibly emerging cognitive decline associated with cortical pathogenesis in PD.
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